The only support you have here is the market maker, THAT'S IT, Without news he's the only one holding this up or taking it down.
As for your patience, if you were here in Dec when it dropped to .27 and you didn't sell, why lose your patience now ???
Listen, from the low of .27 in December , This is up 200 pct , we're just going to wait for some news to drive this higher, Right now the MM is in control, he takes it down to buy shares and takes it up to sell those same shares, over and over again, just a waiting game now.
Ya gotta love it
You are correct on that, But these articles on the other hand show the huge potential that is ahead for BGMD, I truly hope that they come up with a great deal with Abbott, one that does not include the sale of the company, there is a very good chance that this may be a very big deal down the road.
In their review, Chiu and colleagues concluded that the galectin-3 biomarker “is a
sensitive (78%), specific (93%), and accurate marker for the diagnosis of thyroid cancer.
Research has demonstrated that relative to healthy individuals, galectin-3 levels were significantly elevated P=0.014 in patients with malignancies of the breast, gastrointestinal tract, lung, and ovary, as well as melanoma and non-Hodgkin’s lymphoma.
Of note, when compared to prostate specific antigen PSA levels, galectin-3 consistently distinguished metastatic prostate cancer from cancer-free controls better than did PSA.
implicating galectin-3 as a potential complementary marker in the PSA blood test.
Galectin-3 has the potential to reflect changes in cancer status, as well as uncover other indicators of disease progression including inflammation, angiogenesis, and immunosuppression. The scientific literature demonstrates that elevated serum galectin-3 levels are associated with a variety of cancer types. Overexpression of galectin-3 can be a contributing factor to disease progression and metastasis.
The use of other cancer markers in conjunction with galectin-3 plasma levels may be the best way to utilize this biomarker in cancer progression and treatment evaluation.
In addition, research indicates that finding ways to block galectin-3 expression and/or activity could have an impact on disease outcomes and may contribute to overall treatment success.56 The galectin-3 ELISA assay is presently readily available to clinicians. The preliminary data support the incorporation of galectin-3 testing as a biomarker of cancer progression and as an aid to prognosis determination.
This is a cut down version of this report, To view the full report Google Galectin-3 as an Oncological Biomarker
Presently, galectin-3 testing by enzyme-linked immune-sorbent assay (ELISA) Also has been approved on ( Abbott's ARCHITECT fully-automated immunoassay analyzer ) by the US Food and Drug Administration (FDA) as a serum biomarker in chronic heart failure patients. ( BG Medicine )
Galectin-3 as a biomarker has been confirmed with connections to inflammation, fibrosis, and overall risk of mortality in the general population. A blood serum test has been approved as a biomarker in high-risk cardiovascular patients to monitor potential heart failure. Elevated levels of galectin-3 in the serum have been linked to the development of several different cancers as well as cancer metastasis. Preclinical cancer models have shown galectin-3 to be associated with tumor cell transformation, invasive behavior, and metastasis.
Galectin-3 influences oncogenesis and progression through a variety of pathways both inside and outside the cell. Elevated galectin-3 expression has been linked to several different malignancies, as well as neoplastic progression and therefore has the potential to be a useful biomarker in oncology.
Preliminary research shows potential efficacy as a biomarker for systemic sclerosis, Alzheimer’s disease, and chronic kidney disease.
In vitro studies have shown that increased cellular galectin-3 expression directly correlates with apoptosis resistance in many cancers, including leukemia, breast cancer, and lymphoma.
Just as galectin-3 has been shown to help detect early heart disease, it can also be utilized similarly in oncology. Because studies have shown that galectin-3 is overexpressed in several cancers, it could prove to be a useful diagnostic biomarker.
Could get interesting
It went up 152K in short interest between Jan 15 and Jan 30
On Jan 15 the stock was selling for .41
On Jan 30 the stock was selling for at one point $1.22
I dont understand what your point is !!!!!! ,
Anyone would have done extremely well to have bought at .41 and sold at $1.22 on Jan 30th
Thats how the market works.
This from seeking alpha Feb 2nd concerning Abbott s earnings.
The company's Diagnostic's division is also poised for future growth on the back of FDA clearance for its galectin-3 test that can be used on the ARCHITECT platform. Less
There is IMHO NO possibility that this will be delisted, All that Bgmd has to do is show nasdaq that they have been cleared by the FDA for the galectin 3 test with Abbott's automated immunoassay test and they will be granted another 180 extension, DONE DEAL
The acquisition of Veropharm is a strategic move for the company's Established Pharmaceutical division, especially since it allows it to expand its footprint into Russia, a key emerging market for the company. The acquisition has also given Abbott access to machines that serves Abbott's areas of focus very well. The company's Diagnostic's division is also poised for future growth on the back of FDA clearance for its galectin-3 test that can be used on the ARCHITECT platform.
0.001, P = 0.002, respectively. In case of cirrhotic patients, galectin-3 levels were significantly higher in patients with cirrhosis secondary to HCV compared with HBV P = 0.03. When we evaluated galectin-3 levels in HCC patients, it was found to be 3.92 ng/mL in HCC secondary to hepatitis B and 5.37 ng/mL in HCC secondary to hepatitis C.
Serum galectin-3 levels in patients with chronic HBV or HCV may guide us about progression to cirrhosis or HCC and prognosis of the disease. Especially, galectin-3 levels may be more pronounced in case of HCV.